0

6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer

Benjamin J Buckley, Ashraf Aboelela, Elahe Minaei, Longguang X Jiang, Zhihong Xu, Umar Ali, Karen Fildes, Chen-Yi Cheung, Simon M Cook, Darren C Johnson, Daniel A Bachovchin, Gregory M Cook, Minoti Apte, etc.

J Med Chem. 2018 Sep 27;61(18):8299-8320.

PMID: 30130401

Abstract:

Metastasis is the cause of death in the majority (∼90%) of malignant cancers. The oral potassium-sparing diuretic amiloride and its 5-substituted derivative 5 -N, N-(hexamethylene)amiloride (HMA) reportedly show robust antitumor/metastasis effects in multiple in vitro and animal models. These effects are likely due, at least in part, to inhibition of the urokinase plasminogen activator (uPA), a key protease determinant of cell invasiveness and metastasis. This study reports the discovery of 6-substituted HMA analogs that show nanomolar potency against uPA, high selectivity over related trypsin-like serine proteases, and minimal inhibitory effects against epithelial sodium channels (ENaC), the diuretic and antikaliuretic target of amiloride. Reductions in lung metastases were demonstrated for two analogs in a late-stage experimental mouse metastasis model, and one analog completely inhibited formation of liver metastases in an orthotopic xenograft mouse model of pancreatic cancer. The results support further evaluation of 6-substituted HMA derivatives as uPA-targeting anticancer drugs.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP1428951 5-(N,N-Hexamethylene)amiloride 5-(N,N-Hexamethylene)amiloride 1428-95-1 Price
qrcode